Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 13827 | 747 | 31.7 | 66% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ETOPOSIDE PHOSPHATE | Author keyword | 21 | 71% | 2% | 17 |
| 2 | ETOPOSIDE | Author keyword | 20 | 10% | 26% | 191 |
| 3 | ORAL ETOPOSIDE | Author keyword | 7 | 30% | 3% | 19 |
| 4 | TENIPOSIDE | Author keyword | 4 | 21% | 2% | 18 |
| 5 | HLTH SCI CLIN PHARM | Address | 3 | 57% | 1% | 4 |
| 6 | ROSWELL PK MEM MED | Address | 3 | 100% | 0% | 3 |
| 7 | PHARMACEUT 332 N LAUDERDALE | Address | 3 | 60% | 0% | 3 |
| 8 | ETOPOSIDE CATECHOL | Author keyword | 2 | 67% | 0% | 2 |
| 9 | INJECTABLE DOSAGE FORMS | Author keyword | 2 | 67% | 0% | 2 |
| 10 | SCHEDULE DEPENDENCY | Author keyword | 2 | 28% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ETOPOSIDE PHOSPHATE | 21 | 71% | 2% | 17 | Search ETOPOSIDE+PHOSPHATE | Search ETOPOSIDE+PHOSPHATE |
| 2 | ETOPOSIDE | 20 | 10% | 26% | 191 | Search ETOPOSIDE | Search ETOPOSIDE |
| 3 | ORAL ETOPOSIDE | 7 | 30% | 3% | 19 | Search ORAL+ETOPOSIDE | Search ORAL+ETOPOSIDE |
| 4 | TENIPOSIDE | 4 | 21% | 2% | 18 | Search TENIPOSIDE | Search TENIPOSIDE |
| 5 | ETOPOSIDE CATECHOL | 2 | 67% | 0% | 2 | Search ETOPOSIDE+CATECHOL | Search ETOPOSIDE+CATECHOL |
| 6 | INJECTABLE DOSAGE FORMS | 2 | 67% | 0% | 2 | Search INJECTABLE+DOSAGE+FORMS | Search INJECTABLE+DOSAGE+FORMS |
| 7 | SCHEDULE DEPENDENCY | 2 | 28% | 1% | 5 | Search SCHEDULE+DEPENDENCY | Search SCHEDULE+DEPENDENCY |
| 8 | ADAPTIVE DOSING | 1 | 50% | 0% | 2 | Search ADAPTIVE+DOSING | Search ADAPTIVE+DOSING |
| 9 | ETOPOSIDE DOSAGE | 1 | 100% | 0% | 2 | Search ETOPOSIDE+DOSAGE | Search ETOPOSIDE+DOSAGE |
| 10 | PIPERINE ANALOGUE | 1 | 100% | 0% | 2 | Search PIPERINE+ANALOGUE | Search PIPERINE+ANALOGUE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | VP 16 213 | 48 | 40% | 12% | 93 |
| 2 | UNBOUND ETOPOSIDE | 41 | 85% | 3% | 22 |
| 3 | VP16 213 | 25 | 63% | 3% | 25 |
| 4 | STRANDED PHI X174 DNA | 21 | 90% | 1% | 9 |
| 5 | TENIPOSIDE | 12 | 29% | 5% | 35 |
| 6 | ORTHO QUINONE | 10 | 73% | 1% | 8 |
| 7 | ORAL ETOPOSIDE | 9 | 16% | 7% | 53 |
| 8 | HIGH DOSE ETOPOSIDE | 8 | 27% | 3% | 25 |
| 9 | VM 26 | 5 | 26% | 2% | 16 |
| 10 | CONTINUOUS INFUSION ETOPOSIDE | 4 | 47% | 1% | 7 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Pharmacokinetic optimisation of treatment with oral etoposide | 2004 | 35 | 146 | 73% |
| Camptothecin and podophyllotoxin derivatives - Inhibitors of topoisomerase I and II - Mechanisms of action, pharmacokinetics and toxicity profile | 2006 | 50 | 149 | 28% |
| Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions | 2013 | 2 | 96 | 55% |
| THE CLINICAL-PHARMACOLOGY OF ETOPOSIDE AND TENIPOSIDE | 1987 | 171 | 95 | 72% |
| Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide | 2014 | 2 | 42 | 36% |
| Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information | 2010 | 5 | 27 | 48% |
| Level of evidence for therapeutic drug monitoring for etoposide after oral administration | 2011 | 0 | 17 | 94% |
| ETOPOSIDE - 20 YEARS LATER - REVIEW | 1995 | 62 | 185 | 30% |
| ETOPOSIDE AND TENIPOSIDE - BIOANALYSIS, METABOLISM AND CLINICAL PHARMACOKINETICS | 1988 | 36 | 67 | 91% |
| Etoposide for the treatment of paediatric tumours: What is the best way to give it? | 1996 | 9 | 54 | 78% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HLTH SCI CLIN PHARM | 3 | 57% | 0.5% | 4 |
| 2 | ROSWELL PK MEM MED | 3 | 100% | 0.4% | 3 |
| 3 | PHARMACEUT 332 N LAUDERDALE | 3 | 60% | 0.4% | 3 |
| 4 | PEDIAT PHARMACOKINET THER EUT | 1 | 11% | 1.6% | 12 |
| 5 | PEDIAT PHARMACOKINET THER EUT PEDIAT | 1 | 21% | 0.4% | 3 |
| 6 | HAEMATOL L 124 | 1 | 50% | 0.1% | 1 |
| 7 | HAEMATOL L 4042 | 1 | 50% | 0.1% | 1 |
| 8 | HLTH SCI PHARM CLIN PHARMACOL | 1 | 50% | 0.1% | 1 |
| 9 | HLTH SCI PHARM PEDIAT | 1 | 50% | 0.1% | 1 |
| 10 | PEDIATR PHARMACOKINET THER EUT | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000195657 | PODOPHYLLOTOXIN//DEOXYPODOPHYLLOTOXIN//PHARMACEUT DESIGN SYNTH |
| 2 | 0.0000121913 | CALVERT FORMULA//CHATELUT FORMULA//SKI 2053R |
| 3 | 0.0000106224 | SMALL CELL LUNG CANCER//AMRUBICIN//PROPHYLACTIC CRANIAL IRRADIATION |
| 4 | 0.0000097362 | 7 HYDROXYMETHOTREXATE//GLUCARPIDASE//HIGH DOSE METHOTREXATE |
| 5 | 0.0000081108 | URACIL ARABINOSIDE//ARA CTP//CYTOSINE ARABINOSIDE |
| 6 | 0.0000073214 | HYPERSENSITIVITY REACTIONS//HYPERSENSITIVITY REACTION//CARBOPLATIN HYPERSENSITIVITY |
| 7 | 0.0000071639 | N N N TRIETHYLENEPHOSPHORAMIDE//THIOTEPA MERCAPTURATE//TEPA |
| 8 | 0.0000068715 | MODIFIED ANTIBIOT//IDARUBICINOL//IDARUBICIN |
| 9 | 0.0000068271 | BUSULFAN//TREOSULFAN//INTRAVENOUS BUSULFAN |
| 10 | 0.0000058947 | DOSE BANDING//CHEMOTHERAPY DOSING//GRANULOCYTE MACROPHAGE PROGENITOR CELLS CFU GM |